Stockscreener 앱 받기
29.49
7.90%
2.16
전일 마감가:
$27.33
열려 있는:
$27.15
하루 거래량:
2.59M
Relative Volume:
1.17
시가총액:
$3.61B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-7.523
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+17.96%
1개월 성능:
+42.88%
6개월 성능:
+114.32%
1년 성능:
+187.99%
1일 변동 폭
$27.08
$30.01
1주일 범위
$24.82
$30.01
52주 변동 폭
$10.05
$30.01
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.49 | 3.35B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Matsuda Masaru, Arcutis SVP, sells $72k in Arcutis Biotherapeutics stock By Investing.com - Investing.com Canada
Responsive Playbooks and the ARQT Inflection - news.stocktradersdaily.com
Why Arcutis Biotherapeutics Inc. stock appeals to dividend seekersJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Why Arcutis Biotherapeutics Inc. stock is trending among retail tradersFed Meeting & Weekly High Potential Stock Alerts - newser.com
Why Shares in Arcutis Biotherapeutics Surged Again This Week - sharewise.com
Arcutis Biotherapeutics director Gilbert sells $455k in stock By Investing.com - Investing.com Canada
Is Arcutis Biotherapeutics Inc. stock a buy for dividend growthBuy Signal & Comprehensive Market Scan Insights - newser.com
Dir Gilbert Files To Sell 16,532 Of Arcutis Biotherapeutics Inc [ARQT] - TradingView
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis - MSN
What moving averages say about Arcutis Biotherapeutics Inc.July 2025 Reactions & Technical Entry and Exit Alerts - newser.com
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Historical volatility pattern of Arcutis Biotherapeutics Inc. visualized2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
Arcutis Biotherapeutics Inc Stock Analysis and ForecastMarket Sentiment Indicators & Double Or Triple Returns - earlytimes.in
Arcutis Biotherapeutics stock hits 52-week high at $27.09 By Investing.com - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - sharewise.com
Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k By Investing.com - Investing.com South Africa
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k - Investing.com
Dir Krishnamohan Sells 40,504 ($939.5K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView
Arcutis Biotherapeutics stock rises on FDA acceptance of pediatric psoriasis drug - Investing.com
Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve - MarketScreener
FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis - HCPLive
FDA Evaluates Arcutis (ARQT) Application to Expand ZORYVE Use in Young Children - GuruFocus
FDA accepts Arcutis’ application for psoriasis cream in children By Investing.com - Investing.com Canada
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times
Arcutis Biotherapeutics Announces PDUFA Target Action Date for ZORYVE® Cream 0.3% Indication Expansion in Pediatric Plaque Psoriasis - Quiver Quantitative
Arcutis (NASDAQ: ARQT) sNDA for ZORYVE Cream Accepted, PDUFA June 29 2026 target date - Stock Titan
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averages2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
What the charts say about Arcutis Biotherapeutics Inc. todayEntry Point & AI Forecasted Entry/Exit Points - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fears2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cuts2025 Geopolitical Influence & Fast Entry Momentum Alerts - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Multi asset correlation models including Arcutis Biotherapeutics Inc.July 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Why Arcutis Biotherapeutics Inc. stock attracts high net worth investorsPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Is Arcutis Biotherapeutics Inc. a candidate for recovery playWall Street Watch & Low Drawdown Trading Strategies - newser.com
Arcutis completes enrollment in infant atopic dermatitis study By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):